Tesamorelin cost comes down to which product is being priced. A June 26, 2026 public source lists Egrifta's wholesale acquisition cost, or WAC—the manufacturer's list price to wholesalers before rebates—at $72,000 a year, about $6,000 a month. A current public cash quote for one 28-day Egrifta WR kit is much higher at $10,708.84. Insurance can make the brand cost far less, but usually only for its narrow HIV-related use. Compounded tesamorelin is a different, generally cash-pay route.
Those numbers look contradictory. They aren't. List price, pharmacy cash price, insurance-negotiated price, and a patient's copay all measure different things.
Tesamorelin cost at a glance
Here is the simplest useful comparison. The wholesale figure is a benchmark, not a bill. The cash quote is what one price guide showed without insurance when checked on September 6, 2026, and a local specialty pharmacy may quote something else.
| Route | Public price benchmark | What changes the amount paid |
|---|---|---|
| Egrifta brand WAC | $72,000 yearly, about $6,000 monthly | Insurer discounts and rebates are not included |
| Egrifta WR cash price | About $10,709 for one 28-day kit | Pharmacy, location, availability, and discounts |
| Egrifta WR with insurance | No single public amount | Plan coverage, prior authorization (insurer review before coverage), deductible, and copay |
| Compounded tesamorelin | Current price shown in the live card below | Provider program, pharmacy, formulation, and what services are included |
Egrifta WR is the brand product. The FDA label revised in March 2025 says it is for excess abdominal fat in adults with HIV and lipodystrophy, meaning an unusual change in where the body stores fat. It is not labeled as a general weight-loss medicine.
Why brand Egrifta WR costs so much
Egrifta WR serves a small, specific patient population. Its price also carries the costs of developing an approved product, manufacturing a sterile injection, maintaining the brand's regulatory file, and moving it through specialty-pharmacy distribution. The kit contains four vials plus mixing and injection supplies for 28 days.
There is no true generic price to compare. FDA's Purple Book record lists Egrifta WR as marketed but does not list a licensed biosimilar, a competing version much like a generic. Less direct competition helps explain why the sticker price remains high.
The price is attached to a clinical use with human evidence behind it. In a 2010 pooled analysis of two phase 3 trials in 806 adults with HIV and excess abdominal fat, the reported 26-week between-group difference in visceral-fat change was −15.4% for tesamorelin versus placebo; the abstract reports absolute changes of −24 cm² and +2 cm², respectively (Falutz and colleagues, Journal of Clinical Endocrinology & Metabolism). That result applies to adults with HIV and excess abdominal fat, not to everyone seeking fat loss.
Why compounded tesamorelin is cheaper
A compounded medication is prepared by a pharmacy for an individual prescription. It does not carry the Egrifta name, kit, or manufacturer price. It also is not a generic copy with an interchangeable label. That is why comparing only the molecule name can be misleading.
Tesamorelin from Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.
The lower price reflects a different product and supply path, not a coupon on Egrifta WR. The tesamorelin product page and live card show the current Promise price without turning an article into a price sheet that can go stale.
What the tesamorelin and ipamorelin price represents
A tesamorelin-and-ipamorelin product is another distinct prescription, not a bargain version of either Egrifta WR or tesamorelin alone. It combines two named compounds, so its price should be compared with other combination products and with the services included—not milligram for milligram with the brand kit.
The clinical question changes too. Tesamorelin copies a natural growth-hormone-releasing signal, while ipamorelin acts through a different receptor. Tesamorelin and ipamorelin together explains that distinction and the evidence limits in plain language. A provider should decide whether a blend makes sense before its price becomes the deciding factor.
Does insurance cover tesamorelin?
Insurance may cover brand Egrifta WR for HIV-associated lipodystrophy. Expect prior authorization, which means the plan reviews the diagnosis before agreeing to pay. Coverage for general abdominal fat, bodybuilding, anti-aging, or routine weight management is usually excluded because those uses fall outside the label. Compounded tesamorelin is generally paid for directly.
One current example shows how narrow the door can be. UnitedHealthcare's policy effective January 1, 2026 requires an HIV-associated lipodystrophy diagnosis for initial authorization. Renewal requires a documented response, such as reduced visceral fat or waist circumference. Other plans write their own rules, so that policy is an example, not a promise of coverage.
The manufacturer also says its patient-support program can check benefits, offer copay help to eligible commercially insured patients, point people with government insurance toward resources, and provide medicine at no cost to some qualifying patients. Eligibility matters; the posted cash price does not tell anyone what their final bill will be.
Fresh tesamorelin evidence in 2026
As of September 6, 2026, the day this article was written, a systematic review published July 31 combined four randomized trials—studies that assign people to groups by chance—with 909 people living with HIV and lipodystrophy. It found an average visceral-fat reduction of 21.47 square centimeters versus placebo, while also flagging limited long-term safety and durability data (Ditta and colleagues, Journal of the International Association of Providers of AIDS Care).
That is useful context, but it did not create a new labeled use or a new insurance benefit. The evidence still centers on people with HIV-related fat changes. For a fuller look at what the research can and cannot answer, see whether tesamorelin works.
What a fair price comparison includes
Before comparing quotes, put the same items on both sides: the exact product, supply length, medical evaluation, follow-up, lab work, injection supplies, shipping, refill fees, and cancellation terms. A low vial price can stop looking low when everything around it is billed separately. A high brand cash quote may fall sharply after insurance or assistance.
Monitoring matters here. The Egrifta WR label calls for checks of insulin-like growth factor 1, or IGF-1—a blood marker that rises when growth-hormone signaling increases—and blood sugar. The practical cost is therefore more than medication alone. The tesamorelin side-effects guide explains why those checks matter.
The number to compare before deciding
The most honest number is the expected total for the next few months, after coverage and required services, for the exact product prescribed. It should say brand or compounded in writing. It should also say what happens if the provider declines or monitoring changes the plan.
At Promise, a licensed provider reviews every request, and not everyone qualifies. Price can help choose between real options, but it should not choose the medication.